Market news

New CEO-led video series provides investors with straight talk, just the facts, with no B. or corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the inaugural episode hereIRVINE, CA / ACCESS Newswire / September 16, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the launch of "WTF Rob Berman" a new video series that provides the information that investors need to know, in straight talk, with no corporate spin.

Access the video webcast hereIRVINE, CA / ACCESS Newswire / September 11, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

IRVINE, CA/ ACCESS Newswire/ August 27, 2026/ enVVeno Medical Corporation today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference. JTC Team and Virtual Investor Co. are paid consultants to enVVeno Medical Corporation. Any content included in this release shall not be...

Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage ...

Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027 IRVINE, ...

CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / July 15, 2026 / enVVeno ...

New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar Market Opportunity enVVe Pivotal ...